C12 NBD Globotriaosylceramide
C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside.
For research use only. We do not sell to patients.
- CAS No.: 2692623-26-8
- Formula: C54H91N5O21
- Molecular Weight:1146.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
C12 NBD globotriaosylceramide accumulates in human umbilical vascular endothelial cells (HUVECs) treated with the α-galactosidase A inhibitor in a concentration-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Emission (Em)
525
Chemical Information
-
CAS No. 2692623-26-8
-
Molecular Weight 1146.32
-
Formula C54H91N5O21
-
SMILES
O=C(CCCCCCCCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O)N[C@@H](CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@@]4(O[C@@H]([C@@H]([C@@H]([C@H]4O)O)O[C@@]5([C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)[H])CO)[H])O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Kassiani Kytidou, et al. Nicotiana benthamiana α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease. J Biol Chem. 2018 Jun 29;293(26):10042-10058. [Content Brief]
[2]. Janet Hsu, et al. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Release. 2011 Feb 10;149(3):323-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)